secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K/A
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001759425-26-000021
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum completes acquisition of Bluejay Therapeutics with $268.5M PIPE; Bluejay reports 2025 net loss of $101.7M
--------------------------------------------------------------------------------

- Concurrent PIPE raised $268.5M gross at $68.48/sh including pre-funded warrants.
- Bluejay 2025 audited: net loss $101.7M, R&D $87.1M, total assets $85.6M, accumulated deficit $190M.
- Bluejay had substantial doubt about going concern; Mirum committed to fund operations post-close.
- Lead candidate brelovitug (BJT-778) for chronic hepatitis delta is in clinical development.
- Pro forma financials for combined entity filed; acquisition closed Jan 23, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000021/0001759425-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000021/mirm-20260123.htm
  HTML page:      https://secwatch.observer/filing/0001759425-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer